569489673	569489673	CD	B-NP	O
|	|	NN	I-NP	O
BHO	BHO	NN	I-NP	O
|	|	NN	I-NP	O
36767844	36767844	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
6775129	6775129	CD	B-NP	O
|	|	CC	I-NP	O
8/1/2006	8/1/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
HAND	HAND	NNP	I-NP	I-protein
CELLULITIS	CELLULITIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/22/2006	5/22/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
3/6/2006	3/6/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
DEMONT	DEMONT	NNP	B-NP	O
,	,	,	O	O
CRAIG	CRAIG	NNP	B-NP	O
JEWELL	JEWELL	NNP	I-NP	O
MD	MD	NNP	I-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
Cellulitis	Cellulitis	NN	B-NP	O
.	.	.	O	O

LIST	LIST	NN	B-NP	B-protein
OF	OF	IN	B-PP	I-protein
PROBLEMS/DIAGNOSES	PROBLEMS/DIAGNOSES	NNPS	B-NP	B-protein
:	:	:	O	I-protein
1	1	LS	B-LST	I-protein
.	.	.	O	O

Inflammatory	Inflammatory	JJ	B-NP	O
breast	breast	NN	I-NP	O
cancer	cancer	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Type	Type	NN	B-NP	O
II	II	CD	I-NP	O
diabetes	diabete	NNS	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

CHF	CHF	NN	B-NP	B-protein
with	with	IN	B-PP	O
preserved	preserve	VBN	B-NP	O
systolic	systolic	JJ	I-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Obstructive	Obstructive	JJ	B-NP	O
sleep	sleep	NN	I-NP	O
apnea	apnea	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Asthma	Asthma	NN	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Spinal	Spinal	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
with	with	IN	B-PP	O
herniated	herniate	VBN	B-NP	B-cell_type
discs	disc	NNS	I-NP	I-cell_type
.	.	.	O	O

BRIEF	BRIEF	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
Ms.	Ms.	NNP	B-NP	O
Schwarzer	Schwarzer	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
72-year-old	72-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
newly	newly	RB	B-NP	O
diagnosed	diagnose	VBN	I-NP	O
ductal	ductal	JJ	I-NP	O
carcinoma	carcinoma	NN	I-NP	O
and	and	CC	I-NP	O
inflammatory	inflammatory	JJ	I-NP	O
breast	breast	NN	I-NP	O
cancer	cancer	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
breast	breast	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
mass	mass	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
lung	lung	NN	I-NP	O
that	that	WDT	B-NP	O
is	be	VBZ	B-VP	O
suggestive	suggestive	JJ	B-ADJP	O
of	of	IN	B-PP	O
likely	likely	JJ	B-NP	O
stage	stage	NN	I-NP	O
IV	IV	CD	I-NP	O
disease	disease	NN	I-NP	O
who	who	WP	B-NP	O
has	have	VBZ	B-VP	O
also	also	RB	B-ADVP	O
multiple	multiple	JJ	B-NP	O
other	other	JJ	I-NP	O
medical	medical	JJ	I-NP	O
problem	problem	NN	I-NP	O
including	include	VBG	B-PP	O
diabetes	diabete	NNS	B-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
two-day	two-day	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
right	right	NN	B-NP	O
and	and	CC	O	O
left	leave	VBD	B-VP	O
finger	finger	NN	B-NP	O
warmth	warmth	NN	I-NP	O
,	,	,	O	O
tenderness	tenderness	NN	B-NP	O
and	and	CC	I-NP	O
swelling	swelling	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
undergoing	undergo	VBG	I-VP	O
chemotherapy	chemotherapy	NN	B-NP	O
with	with	IN	B-PP	O
Adriamycin	Adriamycin	NN	B-NP	O
and	and	CC	I-NP	O
cytoxan	cytoxan	NN	I-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
cycle	cycle	NN	I-NP	O
2	2	CD	I-NP	O
on	on	IN	B-PP	O
9/6/06	9/6/06	CD	B-NP	O
and	and	CC	O	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
feel	feel	VB	I-VP	O
like	like	IN	B-PP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
recovering	recover	VBG	I-VP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
approximately	approximately	RB	B-NP	O
three	three	CD	I-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
spinal	spinal	JJ	I-NP	O
MRI	MRI	NN	I-NP	O
obtained	obtain	VBN	B-VP	O
on	on	IN	B-PP	O
Tuesday	Tuesday	NNP	B-NP	O
to	to	TO	B-VP	O
evaluate	evaluate	VB	I-VP	O
her	her	PRP$	B-NP	O
spinal	spinal	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
was	be	VBD	B-VP	O
uneventful	uneventful	JJ	B-ADJP	O
but	but	CC	I-ADJP	O
later	later	JJ	I-ADJP	O
on	on	IN	B-PP	O
that	that	DT	B-NP	O
day	day	NN	I-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
redness	redness	NN	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
dorsum	dorsum	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
hand	hand	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
area	area	NN	I-NP	O
in	in	IN	B-PP	O
which	which	WDT	B-NP	O
her	her	PRP$	B-NP	O
IV	IV	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
per	per	IN	B-PP	O
the	the	DT	B-NP	O
MRI	MRI	NN	I-NP	B-protein
.	.	.	O	O

The	The	DT	B-NP	O
following	follow	VBG	I-NP	O
morning	morning	NN	I-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
pustular	pustular	JJ	I-NP	O
lesion	lesion	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
fourth	fourth	JJ	I-NP	O
digit	digit	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
hand	hand	NN	I-NP	O
distal	distal	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
dorsal	dorsal	JJ	I-NP	O
redness	redness	NN	I-NP	O
and	and	CC	O	O
went	go	VBD	B-VP	O
to	to	TO	B-PP	O
EH	EH	NNP	B-NP	O
Urgent	Urgent	NNP	I-NP	O
Care	Care	NNP	I-NP	O
where	where	WRB	B-ADVP	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
one	one	CD	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
a	a	DT	B-NP	O
p.o.	p.o.	FW	I-NP	O
script	script	NN	I-NP	O
for	for	IN	B-PP	O
Augmentin	Augmentin	NNP	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
home	home	NN	B-ADVP	O
but	but	CC	B-PP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
expulsive	expulsive	JJ	B-NP	O
diarrhea	diarrhea	NN	I-NP	O
and	and	CC	O	O
vomiting	vomit	VBG	B-VP	O
on	on	IN	B-PP	O
that	that	DT	B-NP	O
evening	evening	NN	I-NP	O
,	,	,	O	O
was	be	VBD	B-VP	O
not	not	RB	O	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
tolerate	tolerate	VB	I-VP	O
her	her	PRP$	B-NP	O
oral	oral	JJ	I-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
next	next	JJ	I-NP	O
day	day	NN	I-NP	O
she	she	PRP	B-NP	O
noticed	notice	VBD	B-VP	O
a	a	DT	B-NP	O
similar	similar	JJ	I-NP	O
lesion	lesion	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
fourth	fourth	JJ	I-NP	O
digit	digit	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
hand	hand	NN	I-NP	O
looking	look	VBG	B-VP	O
much	much	RB	B-ADVP	O
like	like	IN	B-PP	O
that	that	DT	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
hand	hand	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
returned	return	VBD	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
TMHMC	TMHMC	NN	I-NP	O
urgent	urgent	JJ	I-NP	O
care	care	NN	I-NP	O
for	for	IN	B-PP	O
one	one	CD	B-NP	O
more	more	JJR	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
then	then	RB	I-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
for	for	IN	B-PP	O
IV	IV	CD	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
denies	deny	VBZ	B-VP	O
any	any	DT	B-NP	O
cat	cat	NN	I-NP	O
bites	bite	NNS	I-NP	O
,	,	,	O	O
travel	travel	NN	B-NP	O
,	,	,	O	O
soil	soil	NN	B-NP	O
or	or	CC	O	O
water	water	NN	B-NP	O
contract	contract	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
no	no	DT	B-NP	O
bruises	bruise	NNS	I-NP	O
,	,	,	O	O
scrapes	scrape	NNS	B-NP	O
or	or	CC	O	O
previous	previous	JJ	B-NP	O
lesions	lesion	NNS	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
detailed	detail	VBN	B-VP	O
above	above	RB	B-ADVP	O
.	.	.	O	O

MEDICINES	MEDICINES	NNS	B-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
40	40	CD	I-NP	O
units	unit	NNS	I-NP	O
nightly	nightly	RB	B-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Zestril	Zestril	NNP	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Cardizem	Cardizem	NN	B-NP	O
ER	ER	NN	I-NP	O
240	240	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	RB	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Procrit	Procrit	NN	B-NP	O
40000	40000	CD	B-NP	O
units	unit	NNS	I-NP	O
weekly	weekly	RB	B-ADVP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Pamidronate	Pamidronate	NN	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O
with	with	IN	B-PP	O
chemotherapy	chemotherapy	NN	B-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

AC	AC	NN	B-NP	O
chemo	chemo	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Neulasta	Neulasta	NNP	B-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Ativan	Ativan	NNP	B-NP	O
p.r.n.	p.r.n.	NNP	I-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Isosorbide	Isosorbide	NN	B-NP	O
dinitrate	dinitrate	NN	I-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

Allegra	Allegra	NNP	B-NP	O
60	60	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
ALLERGIES	ALLERGIES	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Percodan	Percodan	NNP	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Halothane	Halothane	NN	B-NP	O
causing	cause	VBG	B-VP	O
fevers	fever	NNS	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Atenolol	Atenolol	NN	B-NP	O
causing	cause	VBG	B-VP	O
sweating	sweating	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Sulfa	Sulfa	NNP	B-NP	O
causes	cause	VBZ	B-VP	O
a	a	DT	B-NP	O
rash	rash	NN	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
lives	live	VBZ	B-VP	O
alone	alone	RB	B-ADVP	O
in	in	IN	B-PP	O
Te	Te	NNP	B-NP	O
She	She	NNP	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
very	very	RB	I-NP	O
sad	sad	JJ	I-NP	O
social	social	JJ	I-NP	O
history	history	NN	I-NP	O
in	in	IN	B-PP	O
which	which	WDT	B-NP	O
her	her	PRP$	B-NP	O
husband	husband	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
TX	TX	NN	I-NP	O
war	war	NN	I-NP	O
veteran	veteran	NN	I-NP	O
and	and	CC	O	O
came	come	VBD	B-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Ra	Ra	NNP	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
service	service	NN	B-NP	O
connected	connect	VBN	B-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
pofield	pofield	NN	I-NP	O
medical	medical	JJ	I-NP	O
center	center	NN	I-NP	O
of	of	IN	B-PP	O
psychiatric	psychiatric	JJ	B-NP	O
disturbances	disturbance	NNS	I-NP	O
following	follow	VBG	B-PP	O
his	his	PRP$	B-NP	O
tour	tour	NN	I-NP	O
of	of	IN	B-PP	O
duty	duty	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBD	I-VP	O
three	three	CD	B-NP	O
sons	son	NNS	I-NP	O
,	,	,	O	O
two	two	CD	B-NP	O
twins	twin	NNS	I-NP	O
who	who	WP	B-NP	O
died	die	VBD	B-VP	O
earlier	early	JJR	B-ADVP	O
in	in	IN	B-PP	O
life	life	NN	B-NP	O
of	of	IN	B-PP	O
some	some	DT	B-NP	O
unspecified	unspecified	JJ	I-NP	O
heart	heart	NN	I-NP	O
illness	illness	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
third	third	JJ	I-NP	O
son	son	NN	I-NP	O
who	who	WP	B-NP	O
died	die	VBD	B-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
age	age	NN	I-NP	O
of	of	IN	B-PP	O
21	21	CD	B-NP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
long	long	JJ	I-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
with	with	IN	B-PP	O
clear	clear	JJ	B-NP	O
cell	cell	NN	I-NP	O
sarcoma	sarcoma	NN	I-NP	O
of	of	IN	B-PP	O
bone	bone	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
lives	live	VBZ	B-VP	O
alone	alone	RB	B-ADVP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
second	second	JJ	I-NP	O
floor	floor	NN	I-NP	O
walkup	walkup	NN	I-NP	O
in	in	IN	B-PP	O
Du	Du	NNP	B-NP	O
near	near	IN	B-PP	O
Inslareca	Inslareca	NNP	B-NP	O
Cou	Cou	NNP	I-NP	O
Pla	Pla	NNP	I-NP	O
She	She	NNP	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
distant	distant	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
tobacco	tobacco	NN	B-NP	O
50	50	CD	B-NP	O
years	year	NNS	I-NP	O
ago	ago	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
rarely	rarely	RB	B-ADVP	O
drinks	drink	VBZ	B-VP	O
alcohol	alcohol	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
friend	friend	NN	I-NP	O
and	and	CC	I-NP	O
healthcare	healthcare	NN	I-NP	O
proxy	proxy	NN	I-NP	O
is	be	VBZ	B-VP	O
Ezekiel	Ezekiel	NNP	B-NP	O
Stoviak	Stoviak	NNP	I-NP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
phone	phone	NN	I-NP	O
#	#	#	B-NP	O
288-186-2874	288-186-2874	CD	I-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
breast	breast	NN	B-NP	O
cancer	cancer	NN	I-NP	O
.	.	.	O	O

Mother	Mother	NNP	B-NP	O
had	have	VBD	B-VP	O
colon	colon	NN	B-NP	O
cancer	cancer	NN	I-NP	O
.	.	.	O	O

Three	Three	CD	B-NP	O
aunts	aunt	NNS	I-NP	O
and	and	CC	O	O
maternal	maternal	JJ	B-NP	O
grandmother	grandmother	NN	I-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
colon	colon	NN	B-NP	O
cancer	cancer	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
son	son	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
clear	clear	JJ	I-NP	O
cell	cell	NN	I-NP	O
sarcoma	sarcoma	NN	I-NP	O
of	of	IN	B-PP	O
bone	bone	NN	B-NP	O
.	.	.	O	O

REVIEW	REVIEW	NNP	B-NP	O
OF	OF	IN	B-PP	O
SYSTEMS	SYSTEMS	NNP	B-NP	O
:	:	:	O	O
Positive	Positive	JJ	B-ADJP	O
for	for	IN	B-PP	O
nausea	nausea	NN	B-NP	O
,	,	,	I-NP	O
vomiting	vomiting	NN	I-NP	O
,	,	,	I-NP	O
diarrhea	diarrhea	NN	I-NP	O
,	,	,	I-NP	O
lightheadedness	lightheadedness	NN	I-NP	O
and	and	CC	I-NP	O
dizziness	dizziness	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
chemo	chemo	NN	I-NP	O
but	but	CC	O	O
she	she	PRP	B-NP	O
denies	deny	VBZ	B-VP	O
fevers	fever	NNS	B-NP	O
,	,	,	O	O
chills	chill	NNS	B-NP	O
,	,	,	O	O
sweats	sweat	NNS	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
72	72	CD	I-NP	O
to	to	TO	I-NP	O
96	96	CD	I-NP	O
hours	hour	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
on	on	IN	B-PP	O
3/28/06	3/28/06	CD	B-NP	O
two	two	CD	I-NP	O
days	day	NNS	I-NP	O
after	after	IN	B-PP	O
her	her	PRP$	B-NP	O
chemo	chemo	NN	I-NP	O
but	but	CC	O	O
none	none	NN	B-NP	O
since	since	IN	B-PP	O
and	and	CC	I-PP	O
in	in	IN	I-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
leading	lead	VBG	B-VP	O
up	up	IN	B-ADVP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

ADMISISON	ADMISISON	NNP	B-NP	O
PHYSICAL	PHYSICAL	NNP	I-NP	O
EXAM	EXAM	NNP	I-NP	O
:	:	:	O	O
Temperature	Temperature	NN	B-NP	O
was	be	VBD	B-VP	O
98.9	98.9	CD	B-NP	O
,	,	,	O	O
pulse	pulse	NN	B-NP	O
98	98	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
132/55	132/55	CD	I-NP	O
,	,	,	I-NP	O
respiratory	respiratory	JJ	I-NP	O
rate	rate	NN	I-NP	O
16	16	CD	I-NP	O
,	,	,	O	O
95	95	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
physical	physical	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
alopecia	alopecia	NN	B-NP	O
and	and	CC	I-NP	O
obesity	obesity	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
distress	distress	NN	I-NP	O
,	,	,	O	O
alert	alert	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
oriented	orient	VBN	I-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
pupils	pupil	NNS	I-NP	O
were	be	VBD	B-VP	O
equal	equal	JJ	B-ADJP	O
,	,	,	I-ADJP	O
round	round	JJ	I-ADJP	O
and	and	CC	I-ADJP	O
reactive	reactive	JJ	I-ADJP	O
.	.	.	O	O

Conjunctivae	Conjunctivae	NNP	B-NP	O
were	be	VBD	B-VP	O
pink	pink	JJ	B-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
anicteric	anicteric	JJ	B-ADJP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
oropharynx	oropharynx	NN	I-NP	O
was	be	VBD	B-VP	O
clear	clear	JJ	B-ADJP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	B-protein
was	be	VBD	B-VP	O
hard	hard	JJ	B-ADJP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
neck	neck	NN	B-NP	O
fullness	fullness	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
wears	wear	VBZ	B-VP	O
hearing	hearing	NN	B-NP	O
aids	aid	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
lungs	lung	NNS	I-NP	O
were	be	VBD	B-VP	O
clear	clear	JJ	B-ADJP	O
to	to	TO	B-PP	O
auscultation	auscultation	NN	B-NP	O
except	except	IN	B-PP	O
for	for	IN	B-PP	O
decreased	decrease	VBN	B-NP	O
breath	breath	NN	I-NP	O
sounds	sound	VBZ	B-VP	O
with	with	IN	B-PP	O
crackles	crackle	NNS	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
base	base	NN	I-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
regular	regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
S1	S1	NN	I-NP	O
,	,	,	O	O
S2	S2	NN	B-NP	B-protein
and	and	CC	O	O
no	no	DT	B-NP	O
murmur	murmur	NN	I-NP	O
,	,	,	O	O
rubs	rub	NNS	B-NP	O
or	or	CC	I-NP	O
gallops	gallop	NNS	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
benign	benign	JJ	I-ADJP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
had	have	VBD	B-VP	O
trace	trace	NN	B-NP	O
to	to	TO	B-PP	O
1	1	CD	B-NP	O
+	+	SYM	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
approximately	approximately	RB	I-NP	O
4	4	CD	I-NP	O
x	x	NN	I-NP	O
2	2	CD	B-NP	O
cm	cm	NN	I-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
redness	redness	NN	B-NP	O
but	but	CC	O	O
no	no	DT	B-NP	O
swelling	swelling	NN	I-NP	O
,	,	,	O	O
positive	positive	JJ	B-NP	O
warmth	warmth	NN	I-NP	O
and	and	CC	O	O
positive	positive	JJ	B-NP	O
tenderness	tenderness	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
dorsal	dorsal	JJ	I-NP	O
surface	surface	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
hand	hand	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
pustular	pustular	JJ	I-NP	O
lesion	lesion	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
fourth	fourth	JJ	I-NP	O
digit	digit	NN	I-NP	O
and	and	CC	I-NP	O
right	right	JJ	I-NP	O
third	third	JJ	I-NP	O
digit	digit	NN	I-NP	O
that	that	WDT	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
I	I	NNP	B-NP	O
&	&	CC	I-NP	O
D	D	NNP	I-NP	O
in	in	IN	B-PP	O
AH	AH	NNP	B-NP	O
Urgent	Urgent	NNP	I-NP	O
Care	Care	NNP	I-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
DATA	DATA	NN	I-NP	O
:	:	:	O	O
Labs	Lab	NNS	B-NP	B-protein
are	be	VBP	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
creatinine	creatinine	NN	B-NP	O
of	of	IN	B-PP	O
1	1	CD	B-NP	O
,	,	,	O	O
white	white	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
4.33	4.33	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	O
of	of	IN	B-PP	O
25.5	25.5	CD	B-NP	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
of	of	IN	B-PP	O
108	108	CD	B-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
leftward	leftward	JJ	I-NP	O
axis	axis	NN	I-NP	O
and	and	CC	I-NP	O
first	first	JJ	I-NP	O
degree	degree	NN	I-NP	O
AV	AV	NN	I-NP	O
block	block	NN	I-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
was	be	VBD	B-VP	O
unremarkable	unremarkable	JJ	B-ADJP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
PROBLEM	PROBLEM	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
72-year-old	72-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
stage	stage	NN	B-NP	O
III	III	CD	I-NP	O
or	or	CC	O	O
stage	stage	NN	B-NP	O
IV	IV	CD	I-NP	O
breast	breast	NN	I-NP	O
cancer	cancer	NN	I-NP	O
who	who	WP	B-NP	O
now	now	RB	B-ADVP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
paronychia	paronychia	NN	B-NP	O
and	and	CC	O	O
possible	possible	JJ	B-NP	O
cellulitis	cellulitis	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
and	and	CC	I-NP	O
left	left	JJ	I-NP	O
hands	hand	NNS	I-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
IV	IV	CD	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
given	give	VBN	B-PP	O
the	the	DT	B-NP	O
proximity	proximity	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
recent	recent	JJ	I-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
finger	finger	NN	I-NP	O
lesions	lesion	NNS	I-NP	O
and	and	CC	O	O
dorsal	dorsal	JJ	B-NP	O
right	right	JJ	I-NP	O
hand	hand	NN	I-NP	O
lesions	lesion	NNS	I-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
heal	heal	VB	I-VP	O
within	within	IN	B-PP	O
two	two	CD	B-NP	O
days	day	NNS	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
incision	incision	NN	B-NP	O
and	and	CC	I-NP	O
drainage	drainage	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
hand	hand	NN	I-NP	O
's	's	POS	B-NP	O
pustular	pustular	JJ	I-NP	O
lesion	lesion	NN	I-NP	O
with	with	IN	B-PP	O
improved	improve	VBN	B-NP	O
speed	speed	NN	I-NP	O
of	of	IN	B-PP	O
healing	heal	VBG	B-VP	O
and	and	CC	O	O
decreased	decrease	VBN	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
48	48	CD	B-NP	O
hours	hour	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
Keflex	Keflex	NNP	B-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
time	time	NN	I-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
redness	redness	NN	B-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
forearm	forearm	NN	I-NP	O
that	that	WDT	B-NP	O
measured	measure	VBD	B-VP	O
approximately	approximately	RB	B-NP	O
6	6	CD	I-NP	O
cm	cm	NN	I-NP	O
x	x	SYM	B-NP	O
4	4	CD	B-NP	O
cm	cm	NN	I-NP	O
in	in	IN	B-PP	O
area	area	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
lesion	lesion	NN	I-NP	O
was	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
erythematous	erythematous	JJ	I-NP	B-protein
base	base	NN	I-NP	I-protein
with	with	IN	B-PP	O
punctuate	punctuate	JJ	B-NP	O
red	red	JJ	I-NP	O
lesions	lesion	NNS	I-NP	O
that	that	WDT	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
appear	appear	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
blanching	blanch	VBG	I-VP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
same	same	JJ	I-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
very	very	RB	I-NP	O
similar	similar	JJ	I-NP	O
lesion	lesion	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
index	index	NN	I-NP	O
finger	finger	NN	I-NP	O
between	between	IN	B-PP	O
her	her	PRP$	B-NP	O
MCP	MCP	NN	I-NP	O
and	and	CC	I-NP	O
PIP	PIP	NN	I-NP	B-protein
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
IV	IV	CD	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
Infectious	Infectious	JJ	I-NP	O
Disease	Disease	NN	I-NP	O
consultants	consultant	NNS	I-NP	O
were	be	VBD	B-VP	O
called	call	VBN	I-VP	O
to	to	TO	B-VP	O
assist	assist	VB	I-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
management	management	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
evolving	evolve	VBG	I-NP	O
lesions	lesion	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
TTE	TTE	NN	I-NP	B-DNA
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
that	that	WDT	B-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
vegetations	vegetation	NNS	I-NP	O
and	and	CC	O	O
serial	serial	JJ	B-NP	O
blood	blood	NN	I-NP	O
cultures	culture	NNS	I-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
bacteremia	bacteremia	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
Infectious	Infectious	JJ	I-NP	O
Disease	Disease	NN	I-NP	O
consultants	consultant	NNS	I-NP	O
suggested	suggest	VBD	B-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
paronychia	paronychia	NN	B-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
digits	digit	NNS	I-NP	O
with	with	IN	B-PP	O
transfer	transfer	NN	B-NP	O
of	of	IN	B-PP	O
bacterial	bacterial	JJ	B-NP	O
infestation	infestation	NN	I-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
skin	skin	NN	B-NP	O
breakdown	breakdown	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
area	area	NN	I-NP	O
around	around	IN	B-PP	O
her	her	PRP$	B-NP	O
nails	nail	NNS	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
hands	hand	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
concern	concern	NN	I-NP	O
for	for	IN	B-PP	O
septic	septic	JJ	B-NP	O
emboli	embolus	NNS	I-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
treated	treat	VBN	I-VP	O
became	become	VBD	B-VP	O
less	less	RBR	B-ADJP	O
likely	likely	JJ	I-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
new	new	JJ	I-NP	O
lesions	lesion	NNS	I-NP	O
that	that	WDT	B-NP	O
were	be	VBD	B-VP	O
not	not	RB	O	O
in	in	IN	B-PP	O
distribution	distribution	NN	B-NP	O
that	that	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
septic	septic	JJ	B-NP	O
emboli	embolus	NNS	I-NP	O
.	.	.	O	O

48	48	CD	B-NP	O
hours	hour	NNS	I-NP	O
later	later	RB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
again	again	RB	I-VP	O
switched	switch	VBN	I-VP	O
from	from	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
to	to	TO	B-PP	O
Keflex	Keflex	NNP	B-NP	O
and	and	CC	O	O
within	within	IN	B-PP	O
12	12	CD	B-NP	O
hours	hour	NNS	I-NP	O
developed	develop	VBD	B-VP	O
new	new	JJ	B-NP	O
maculopapular	maculopapular	JJ	I-NP	O
rash	rash	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
neck	neck	NN	I-NP	O
and	and	CC	I-NP	O
furuncles	furuncle	NNS	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
and	and	CC	I-NP	O
right	right	JJ	I-NP	O
outer	outer	JJ	I-NP	O
labia	labia	NN	I-NP	O
that	that	WDT	B-NP	O
were	be	VBD	B-VP	O
exquisitely	exquisitely	RB	B-ADJP	O
painful	painful	JJ	I-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
one	one	CD	B-NP	O
more	more	JJR	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
IV	IV	CD	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
and	and	CC	O	O
then	then	RB	B-VP	O
resumed	resume	VBN	I-VP	O
on	on	IN	B-PP	O
Keflex	Keflex	NNP	B-NP	O
.	.	.	O	O

Dermatologists	Dermatologist	NNS	B-NP	O
were	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
to	to	TO	B-VP	O
help	help	VB	I-VP	O
determine	determine	VB	I-VP	O
whether	whether	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
suffering	suffer	VBG	I-VP	O
from	from	IN	B-PP	O
shingles	shingle	NNS	B-NP	O
and	and	CC	O	O
they	they	PRP	B-NP	O
deemed	deem	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
new	new	JJ	I-NP	O
rash	rash	NN	I-NP	O
was	be	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
eczematous	eczematous	JJ	I-ADJP	O
in	in	IN	B-PP	O
nature	nature	NN	B-NP	O
and	and	CC	O	O
topical	topical	JJ	B-NP	O
steroid	steroid	NN	I-NP	O
creams	cream	NNS	I-NP	O
were	be	VBD	B-VP	O
prescribed	prescribe	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
new	new	JJ	I-NP	O
rash	rash	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
neck	neck	NN	I-NP	O
quickly	quickly	RB	B-ADVP	O
resolved	resolve	VBD	B-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
furuncles	furuncle	NNS	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
labia	labia	NN	I-NP	O
were	be	VBD	B-VP	O
symptomatically	symptomatically	RB	I-VP	O
managed	manage	VBN	I-VP	O
with	with	IN	B-PP	O
sitz	sitz	NN	B-NP	O
bath	bath	NN	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
daily	daily	RB	I-NP	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
oral	oral	JJ	I-NP	O
cephalosporin	cephalosporin	NN	I-NP	O
antibiotic	antibiotic	NN	I-NP	O
.	.	.	O	O

Throughout	Throughout	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
evolving	evolve	VBG	B-VP	O
dermatologic	dermatologic	JJ	B-NP	O
findings	finding	NNS	I-NP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
experienced	experience	VBD	B-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
pain	pain	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
them	them	PRP	B-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
continued	continue	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
absolutely	absolutely	RB	B-NP	O
no	no	DT	I-NP	O
systemic	systemic	JJ	I-NP	O
complications	complication	NNS	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
these	these	DT	B-NP	O
lesions	lesion	NNS	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
particular	particular	JJ	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
fever	fever	NN	B-NP	O
at	at	IN	B-ADVP	O
all	all	DT	I-ADVP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
chills	chill	NNS	B-NP	O
or	or	CC	I-NP	O
sweats	sweat	NNS	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
no	no	DT	B-NP	O
new	new	JJ	I-NP	O
heart	heart	NN	I-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	B-cell_line
blood	blood	NN	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
remained	remain	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
throughout	throughout	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
IV	IV	CD	B-NP	O
acyclovir	acyclovir	NN	I-NP	O
when	when	WRB	B-ADVP	O
her	her	PRP$	B-NP	O
new	new	JJ	I-NP	O
rash	rash	NN	I-NP	O
developed	develop	VBN	B-VP	O
and	and	CC	O	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
over	over	RP	B-PRT	O
to	to	TO	B-PP	O
Valtrex	Valtrex	NNP	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
for	for	IN	B-PP	O
management	management	NN	B-NP	O
of	of	IN	B-PP	O
presumed	presume	VBN	B-NP	O
HSV	HSV	NN	I-NP	B-cell_line
infection	infection	NN	I-NP	I-cell_line
though	though	IN	B-SBAR	I-cell_line
cultures	culture	NNS	B-NP	I-cell_line
remained	remain	VBD	B-VP	O
pending	pende	VBG	B-ADJP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
Keflex	Keflex	NNP	B-NP	O
and	and	CC	I-NP	O
Valtrex	Valtrex	NNP	I-NP	O
to	to	TO	B-VP	O
complete	complete	VB	I-VP	O
a	a	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
ten	ten	CD	B-NP	O
days	day	NNS	I-NP	O
on	on	IN	B-PP	O
each	each	DT	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
type	type	NN	B-NP	O
II	II	CD	I-NP	O
diabetes	diabete	NNS	I-NP	O
,	,	,	O	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
weight	weight	NN	I-NP	O
based	based	JJ	I-NP	O
insulin	insulin	NN	I-NP	O
regimen	regimen	NN	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
effect	effect	NN	I-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
resume	resume	VB	I-VP	O
her	her	PRP$	B-NP	B-protein
Lantus	Lantus	NNP	I-NP	I-protein
40	40	CD	I-NP	I-protein
units	unit	NNS	I-NP	I-protein
nightly	nightly	RB	B-ADVP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
clean	clean	JJ	I-NP	O
cath	cath	NN	I-NP	O
in	in	IN	B-PP	O
2005	2005	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
aspirin	aspirin	NN	I-NP	O
,	,	,	O	O
statin	statin	NN	B-NP	O
,	,	,	O	O
Zestril	Zestril	NNP	B-NP	O
,	,	,	O	O
Cardizem	Cardizem	NNP	B-NP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
and	and	CC	O	O
nitrates	nitrate	NNS	B-NP	O
were	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
same	same	JJ	I-NP	O
way	way	NN	I-NP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
takes	take	VBZ	B-VP	O
them	them	PRP	B-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
with	with	IN	B-PP	O
very	very	RB	B-NP	O
well	well	RB	I-NP	O
controlled	controlled	JJ	I-NP	O
blood	blood	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
issues	issue	NNS	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
obstructive	obstructive	JJ	B-NP	O
sleep	sleep	NN	I-NP	O
apnea	apnea	NN	I-NP	O
but	but	CC	O	O
does	do	VBZ	B-VP	O
not	not	RB	I-VP	O
use	use	VB	I-VP	O
CPAP	CPAP	NN	B-NP	B-protein
and	and	CC	O	O
do	do	VBP	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
difficulties	difficulty	NNS	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
oxygenation	oxygenation	NN	I-NP	O
even	even	RB	B-PP	O
while	while	IN	I-PP	O
sleeping	sleep	VBG	B-VP	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	B-ADJP	O
anemic	anemic	JJ	I-ADJP	O
and	and	CC	I-ADJP	O
thrombocytopenic	thrombocytopenic	JJ	I-ADJP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
received	receive	VBD	B-VP	O
one	one	CD	B-NP	O
unit	unit	NN	I-NP	O
of	of	IN	B-PP	O
packed	packed	JJ	B-NP	B-cell_type
red	red	JJ	I-NP	I-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
and	and	CC	O	O
her	her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
through	through	IN	B-PP	O
the	the	DT	B-NP	O
duration	duration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

Oncology	Oncology	NNP	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
ductal	ductal	JJ	B-NP	O
carcinoma	carcinoma	NN	I-NP	O
and	and	CC	I-NP	O
inflammatory	inflammatory	JJ	I-NP	O
breast	breast	NN	I-NP	O
cancer	cancer	NN	I-NP	O
that	that	WDT	B-NP	O
is	be	VBZ	B-VP	O
likely	likely	RB	B-ADJP	O
stage	stage	NN	B-NP	O
IV	IV	CD	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
cycle	cycle	NN	I-NP	O
2	2	CD	I-NP	O
of	of	IN	B-PP	O
16	16	CD	B-NP	O
of	of	IN	B-PP	O
neoadjuvant	neoadjuvant	JJ	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
with	with	IN	B-PP	O
Adriamycin	Adriamycin	NN	B-NP	O
and	and	CC	I-NP	O
cytoxan	cytoxan	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
plan	plan	NN	I-NP	O
for	for	IN	B-PP	O
surgical	surgical	JJ	B-NP	O
removal	removal	NN	I-NP	O
after	after	IN	B-PP	O
her	her	PRP$	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
home	home	NN	B-NP	O
with	with	IN	B-PP	O
VNA	VNA	NN	B-NP	O
services	service	NNS	I-NP	O
and	and	CC	O	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
4	4	CD	I-NP	O
h.	h.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
headache	headache	NN	I-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Lipitor	Lipitor	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	I-NP	O
,	,	,	O	O
bacitracin	bacitracin	NN	B-NP	O
topical	topical	JJ	B-ADJP	O
to	to	TO	B-VP	O
rash	rash	VB	I-VP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
Keflex	Keflex	NNP	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.i.d.	q.i.d.	FW	I-ADVP	O
x5	x5	CD	B-NP	O
days	day	NNS	I-NP	O
starting	start	VBG	B-VP	O
on	on	IN	B-PP	O
2/8/06	2/8/06	CD	B-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
completed	complete	VBN	I-VP	O
on	on	IN	B-PP	O
9/23/06	9/23/06	CD	B-NP	O
,	,	,	O	O
chlorhexidine	chlorhexidine	NN	B-NP	O
three	three	CD	B-NP	O
packets	packet	NNS	I-NP	O
daily	daily	RB	B-VP	O
washing	wash	VBG	I-VP	O
area	area	NN	B-NP	O
of	of	IN	B-PP	O
rash	rash	NN	B-NP	O
,	,	,	O	O
darbepoetin	darbepoetin	NN	B-NP	O
100	100	CD	I-NP	O
mcg	mcg	NN	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
weekly	weekly	RB	I-ADVP	O
,	,	,	O	O
diltiazem	diltiazem	NN	B-NP	O
ER	ER	NN	I-NP	O
240	240	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
ferrous	ferrous	JJ	B-NP	O
sulfate	sulfate	NN	I-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Allegra	Allegra	NNP	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
Lasix	Lasix	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
,	,	,	O	O
hydrocortisone	hydrocortisone	NN	B-NP	O
2.5	2.5	CD	I-NP	O
%	%	NN	I-NP	O
cream	cream	NN	I-NP	O
topically	topically	RB	B-ADVP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
to	to	TO	B-PP	O
rash	rash	NN	B-NP	O
,	,	,	O	O
Dilaudid	Dilaudid	VBD	B-VP	O
2	2	CD	B-NP	O
to	to	TO	B-PP	O
4	4	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
4	4	CD	I-NP	O
h.	h.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
Lantus	Lantus	NNP	B-NP	O
40	40	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
every	every	DT	B-NP	O
evening	evening	NN	I-NP	O
,	,	,	O	O
isosorbide	isosorbide	NN	B-NP	O
dinitrate	dinitrate	NN	I-NP	O
10	10	CD	B-NP	O
mg	mg	NN	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
daily	daily	RB	I-NP	O
,	,	,	O	O
Zestril	Zestril	NNP	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Ativan	Ativan	NNP	B-NP	O
0.5	0.5	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-NP	O
daily	daily	JJ	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
insomnia	insomnia	NN	B-NP	O
and	and	CC	I-NP	O
anxiety	anxiety	NN	I-NP	O
,	,	,	O	O
ocean	ocean	JJ	B-NP	O
nasal	nasal	JJ	I-NP	O
spray	spray	NN	I-NP	O
two	two	CD	B-NP	O
sprays	spray	NNS	I-NP	O
nasally	nasally	RB	B-ADVP	O
four	four	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
multivitamin	multivitamin	NN	B-NP	O
one	one	CD	I-NP	O
tab	tab	NN	I-NP	B-protein
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Valtrex	Valtrex	NNP	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
8	8	CD	I-NP	O
h.	h.	NN	I-NP	O
x21	x21	NN	I-NP	O
doses	dose	NNS	I-NP	O
,	,	,	O	O
triamcinolone	triamcinolone	NN	B-NP	O
cream	cream	NN	I-NP	O
topically	topically	RB	B-ADVP	O
once	once	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

PHYSICIAN	PHYSICIAN	NN	B-NP	O
FOLLOWUP	FOLLOWUP	NN	I-NP	O
PLANS	PLANS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
call	call	VB	I-VP	O
Dr.	Dr.	NNP	B-NP	O
Abed	Abed	NNP	I-NP	O
's	's	POS	B-NP	O
clinic	clinic	NN	I-NP	O
to	to	TO	B-VP	O
make	make	VB	I-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
to	to	TO	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
her	her	PRP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
full	full	JJ	B-NP	O
code	code	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
4-9034970	4-9034970	CD	B-NP	O
CSSten	CSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
CHINN	CHINN	NNP	B-NP	O
,	,	,	O	O
GARFIELD	GARFIELD	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
MASUNAGA	MASUNAGA	NNP	B-NP	O
,	,	,	O	O
BARNEY	BARNEY	NNP	B-NP	O
TRACY	TRACY	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
9250556	9250556	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
2/8/06	2/8/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
2/8/06	2/8/06	CD	B-NP	O

